About

 

 

Who is AlloCyte Pharmaceuticals AG ?

 

AlloCyte Pharmaceuticals AG is a Swiss-based company discovering, developing and commercializing oral next generation allosteric integrin modulators to immune-selectively and durably protect the integrity of organs afflicted by tissue-destructive autoimmunity. The company’s next major target milestone is clinical therapeutic proof-of-concept in a high-priority autoimmune disease.  

​

​

'The hardest thing to see is what is in front of your eyes.'

Johann Wolfgang von Goethe

 

                                                                                                                                                                                                                    

The Need

​

Autoimmunity afflicts 5% to 8% of the global population, and prevalence is rising. While immune modulation and immune ablation have grown into the second-largest research field after oncology, a critical gap remains. Today, no treatment directly and selectively stops the root cause of severe autoimmunity: the immune system destroying its own healthy tissue. As a result, severe tissue-destructive autoimmune diseases continue to carry grave, in part devastating prognoses. AlloCyte was founded to change this reality.

​

 

The Game Change

​

AlloCyte’s oral-use lead program targets a profound immune receptor imbalance of autoimmunity that drives the destruction of healthy self cells by patient's immune system, resulting in irreversible loss of tissue function. AlloCyte's goal is to resolve tissue-destructive autoimmunity by restoring the self-protective immune receptor balance of health.

​

The oral allosteric platform pharmacology to achieve this goal is patent-protected and fully owned by AlloCyte. In vivo studies of AlloCyte's drug candidate in an experimental autoimmune disease model established oral proof-of-principle, also demonstrating excellent tolerability and favorable oral pharmacokinetic properties. Additionally, a translational bridging study utilizing autoimmune patient biomaterials confirmed the intended pharmacodynamic effect profile and the absence of unwanted effects observed with earlier non-allosteric pharmacology. Consequently, the next major milestone for AlloCyte's lead program is oral-use clinical proof-of-concept in an autoimmune disease of high unmet medical need.

 

​

Team of Competency

​

​Founded by a team of reputated drug development veterans - including the creators of market-leading immunology therapeutics and renowned professionals from pharma and academia - AlloCyte has leveraged elite professional networks since its inception. Backed by a mix of public, private, and corporate funding, the company drives integrated drug development collaborations with leading investigators, top-tier academic institutions, and global pharmaceutical partners. Leveraging clinical data informing the roles of AlloCyte's target receptor in health and disease, AlloCyte is expediting its oral lead program to achieve therapeutic proof-of-concept in its first high-priority autoimmune indication.

​